Background: The study objective was to evaluate the impact of oral semaglutide type 2 diabetes (oral sema T2D) on changes in HbA1c and weight outcomes in adults with T2D.
Methods: This retrospective cohort study from October 2019 to September 2021 analyzed a linked US database from IQVIA’s Longitudinal Prescription Claims, Professional Fee Claims, and Ambulatory Electronic Medical Records. Adults with T2D with HbA1c ≥7% were included. Analyses were conducted to compare pre- and post-index (12 months) HbA1c and weight-related outcomes.
Results: The final sample included 398 patients. Over 12 months post-index, mean HbA1c decreased significantly from 8.8% to 7.8% (p<0.001), with 32.4% of patients achieving HbA1c <7.0%. Mean BMI decreased significantly from 35.2 to 34.1 kg/m2 (p<0.001), with the proportion of patients with BMI ≥40.0 kg/m2 decreasing from 25.6% to 20.1%, and the proportion of those with BMI ≥30.0 kg/m2 decreasing from 75.6% to 70.4%. Mean weight decreased significantly from 102.4 to 98.9 kg (p<0.001), with 33.4% and 11.1% of patients experiencing a ≥5% and ≥10% decrease in weight, respectively.
Conclusion: At 12-month follow-up, adults initiating oral sema T2D had statistically significant decreases in HbA1c, weight, and BMI from baseline. Further regression analyses will be conducted to control for covariates.
J. Amamoo: None. R. P. Doshi: Employee; IQVIA Inc. J. Noone: Employee; Novo Nordisk. X. Tan: Employee; Merck & Co., Inc., Novo Nordisk, Stock/Shareholder; Merck & Co., Inc., Novo Nordisk. L. Xie: Employee; Pfizer Inc., Novo Nordisk A/S. C. L. Gamble: Employee; Novo Nordisk. M. Guevarra: Employee; Novo Nordisk. J. Chen: Employee; IQVIA Inc. A. A. King: Advisory Panel; Novo Nordisk, Board Member; JDRF, Speaker's Bureau; Sanofi, Abbott, Dexcom, Inc., Lilly Diabetes.
